At a glance
ClinicalIndex Comparison RecordPhase 2Active· 50 enrolled
Drug / intervention
Curcumin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
In Brief
A Phase 2 clinical trial evaluating Curcumin, Laboratory Biomarker Analysis, and 2 other interventions for Chronic Atrophic Gastritis and Gastric Carcinoma. Active but no longer recruiting, targeting 50 participants across 2 sites in 2 countries.
Detailed Summary
This randomized phase IIb trial studies how well curcumin works in preventing gastric cancer in patients with chronic atrophic gastritis and/or gastric intestinal metaplasia. Curcumin is an antioxidant compound found in plants that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Atrophic Gastritis, Gastric Carcinoma
CountriesHonduras, Puerto Rico
Collaborators--
Timeline
Phase 2Active
20172018201920202021202220232024202520262027
First PostedMay 2016
Enrollment StartApr 2017
Primary CompletionOct 2022
TodayJul 2026
Study CompletionApr 2027
First PostedMay 26, 2016
Enrollment StartApr 4, 2017
Primary CompletionOct 6, 2022
Study CompletionApr 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 10.1 years ago
Interventions
Curcumindrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Placebo Administrationother
Given PO
Quality-of-Life Assessmentother
Ancillary studies